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Abstract

The results of a folate deficiency study affecting cognition in mice suggested the altered
genes may be controlled by a transcription factor known as Zinc Finger Protein 410
(Zfp410). Due to a lack of literature on Zfp410’s interacting proteins and DNA-binding
location, our study aims to further elucidate the role Zfp410 plays in affecting cognition. A
custom antibody was used to determine the Zfp410 isoforms present in mouse and rat
brains. Moreover, the antibody was used to determine the binding partners of Zfp410 in the
brain and locate specific genomic regions/sequences with which it associates in vivo. These
results may further elucidate the molecular pathways of Zfp410 in relation to cognition and
learning.

GENOMIC LOCALIZATION OF ZFP410

4

Determining the Genomic Localization and Binding Partners of Zinc Finger Protein 410
Background
Vitamin B9, or folic acid, has been recognized as an important factor that contributes to
increasing DNA stability and is the limiting reagent for the formation of the primary methylating
agent in the S-adenosylmethionisne (SAM) cycle (Bailey & Gregory, 1999; Abbasi et al., 2018;
Crider et al., 2012). Previous studies have identified folic acid to be a crucial cofactor in amino
acid metabolism. B vitamins serve as a cofactor for homocysteine and aid in the conversion of
homocysteine to the amino acid methionine, which perpetuates the SAM cycle (Bailey &
Gregory, 1999). Studies in humans have found that folate deficiencies led to increased levels of
homocysteine, resulting in cognitive deficits related to memory, learning, and visual spatial
pathways (Fenech, 2012; Kim et al, 2010). Folic acid has been also identified to be heavily
involved in altering gene expression, specifically by gene methylation (Fenech, 2012; Milman,
2012; Crider et al., 2012).
Gene methylation is associated with the repression of a gene, preventing transcription and
the subsequent proteins from being made. This mechanism is done by the act of DNA
methyltransferase enzymes, and it occurs at cytosine residues (Salbaum & Kappen, 2012). The
targeted cytosines are typically followed by a guanosine, known as CpG sites, and regions within
the genome that contains large stretches of these bases are named CpG islands. Promoters for
housekeeping genes may be typically found in these CpG islands, which typically remain
unmethylated (Moore et al, 2013). DNA methylation inhibits promoters from recruiting
transcription factors which leads to gene silencing. While this may be important for regulating
diseases; several studies have found DNA methylation to be crucial during development and cell
differentiation (Salbaum & Kappen, 2012). In addition, DNA methylation may also be the cause
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of diseases, such as cancer, if oncogenes can be transcribed in an unregulated manner. In
contrast, hypermethylation of tumor suppressor genes also produce cancer by inhibiting the
regulators of the oncogenes (Mahmoud & Ali, 2019).
With this knowledge in mind, the aim of the previous study in our lab was to determine if
folic acid altered gene expression in mice (Lawton et al., 2020). It was observed that diets
lacking folic acid led to cognitive defects in mice with corresponding altered gene expression
(Lawton et al., 2020). The genes with altered expression were analyzed using bioinformatics
analysis and suggested two transcription factors, proteins that regulate gene expression, may
control the expression of these altered genes (Figure 1). The two candidates were MafB and
Zinc Finger Protein 410 (Zfp410), and bioinformatics analysis provided a putative binding motif
for each transcription factor (Figure 1). While MafB is a well-known transcription factor that
plays a role in regulating the anti-inflammatory and proliferation response in microglia, Zfp410
may play a more prominent role in neuronal cells. Zfp410 has been identified as a transcription
factor, but the literature lacks what function it has in the brain or which genes it may regulate
(Vinjamur et al., 2021; Lee & Young, 2013; Tanigawa et al., 2019). Previous studies have shown
that Zfp410 has been linked with cognitive deficits in mice and young adults but have not
reported where it can be found on DNA or which proteins it may interact with (Lawton et al.,
2020). Although in our previous study, the expression of Zfp410 was revealed to not be
regulated by folic acid, the data suggests that folic acid plays a role in regulating transcription of
these genes in a diet-dependent manner (Lawton et al., 2020; Salbaum & Kappen, 2012; Ulrich,
2005). Zfp410, although not expressed in a folate-dependent manner might still be regulating
gene expression in a folate-dependent mechanism that affects its ability to form complexes with
other proteins or DNA.
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Figure 1
Position weight matrix showing putative binding site of murine Zfp410 and MafB

Note. Through bioinformatics analysis tools a putative binding site for Zfp410 and MafB were
identified using the mouse genome. Used with permission from Lawton et al. (2020). FolateDependent Cognitive Impairment Associated With Specific Gene Networks in the Adult Mouse
Hippocampus. Frontiers in Nutrition 7, 574730. https://doi:10.3389/fnut.2020.574730.
Since the function of Zfp410 and the mechanisms as to how it might control gene
expression has not been identified, the aim of this study was to determine which proteins Zfp410
interacts with and identify where the transcription factor binds to DNA in the brain. To study the
role Zfp410 plays in cognitive pathways, we decided to switch models from folate deficient mice
to methotrexate injected rats to observe the cognitive deficient behavior in the interest of time
and a more cost-efficient manner. Methotrexate acts as a folate inhibitor of an enzyme in the
SAM cycle and prevents the conversion of homocysteine to methionine (McGrattan et al., 2018).
This process makes a product known as S-adenosylmethionine, which is involved in methylation
of proteins, DNA, and small molecules in the brain. While DNA methylation may be important
for the regulation of genes, methylation of neurotransmitters allows for transport and conversion
of chemicals to other neurotransmitters.
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Like folate deficient diets, methotrexate injection (folate inhibition) results in a cognitive
deficiency in rat models (Lawton et al., 2020; Fardell et al., 2010). A study on rheumatoid
arthritis patients where a low dosage of methotrexate was used as a treatment has correlated
elevated levels of homocysteine with reduced cognitive function, commonly referred to as “brain
fog" after rheumatoid arthritis treatment or chemotherapy (van Ede et al., 2002).
While Zfp410 has been implicated to be involved in the process of cognition and
learning, it is not clear how this transcription factor influences the outcomes of cognitive
deficiency and what pathways its involved in. Our study is centered around the interacting
proteins and the DNA binding sites of this transcription factor within the rat genome. The
identification of these regions may further describe molecular pathways involved in cognition
and learning as well as implicate other protein factors that play important roles in cognitive
pathways.
Aim 1: Characterization of the Custom Polyclonal Zfp410 Antibody
Overview
Since Zfp410 lacks an abundance of commercially available antibodies, previous work on
this project included purchasing the coding DNA of the 39 kDa mouse isoform of Zfp410 to
overexpress and purify Zfp410 from E. coli for antibody production. Once a sufficient amount of
recombinant protein had been purified, it was sent to the Pocono Rabbit Farm and Laboratory to
make a custom polyclonal antibody by injecting some of the purified protein into a rabbit. A preimmune serum sample from the rabbit was received for future experimentation and was later
used as a negative control. After 5 injections, the custom antibody serum from the rabbit was
received. Once obtained, the antibody needed to be characterized using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) followed by western blotting to determine if
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specific antibodies had been made. SDS-PAGE gels are used for separating proteins according to
their molecular weight with a range of 5-250 kDa and utilizing polyacrylamide as the gel matrix.
Sodium dodecyl sulfate (SDS) is an ionic detergent that disrupts cell membranes and is used to
denature proteins for separation. Once separated, the proteins are transferred to a membrane
which allows for binding of the antibody. To prevent non-specific binding, the membrane is
blocked using non-fat dry milk, allowing the milk proteins to cover non-specific regions of the
membrane. The western blot technique allows a specific protein to be identified using an
antibody that is specific to the protein of interest, such as Zfp410. Once the Zfp40 antibody was
characterized and we confirmed the presence of Zfp410 in various extracts, our antibody could
be used to accomplish the aims of the study.
Methods: Extract Preparation and Western Blot
About 150mg of frozen (-80°C) female rat brain tissue was placed in a chilled 15mL
Potter-Elvehjem homogenizer and dounced 20 times on ice in 1mL of lysis buffer (25mM TrisHCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 5% glycerol, and 1 protease inhibitor tablet
per 10 mLs added at the time of use). After 15 minutes of centrifugation in a chilled centrifuge at
15,000 rpm, the supernatant was moved to a fresh 1.5 mL tube and the pellet was discarded. The
supernatant was stored in a -80°C freezer for future use.
A 6% SDS-PAGE gel was prepared using 6% polyacrylamide 1:38, 2mLs of 4X lower
buffer (1.5M Tris Base, 0.4% sodium dodecyl sulfate, pH adjusted to 8.8) brought to 8mLs with
reverse osmosis (RO) water. After several inversions of the tube, 45μL of 10% ammonium
persulfate (APS) and 12μL of TEMED (tetramethylethylenediamine) were added to the tube.
After mixing quickly, the solution was added to the gel apparatus using a 1 mL disposable
transfer pipette. Any bubbles at the top of the interface were removed by adding a few drops of
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water-saturated butanol. While solidifying, the upper gel consisted of 3% polyacrylamide (1:38
ratio of bis:acrylamide), 2mLs of upper buffer (500mM Tris Base, 0.4% SDS, adjusted pH to
6.8) brought to 5mLs with RO water. After pouring off the butanol once the lower gel was
solidified, 30μL of 10% APS and 8μL of TEMED were added to the upper gel tube and mixed
quickly. A clean 1mL disposable transfer pipette was used to add the upper gel solution on top of
the solidified lower gel, filling the gel apparatus until it reached the top. A 10-well comb was
added immediately after, and the solution was allowed to solidify. Once the gel was fully
solidified, the comb was removed, and the gel was prepared to run. The gels were removed and
placed in the SDS-PAGE running apparatus. After 200mLs of 1X SDS running buffer (192mM
glycine, 25mMTris base, 0.1% SDS) was added to the middle chamber of the running apparatus,
500mLs of the running buffer was added to the outer chamber of the system. The rat brain
extract was prepared for SDS-PAGE by centrifugation in a chilled centrifuge for 10 minutes at
15,000 rpm. After 10μL of the supernatant was removed to a new tube, 10μL of 2x Laemmli
sample buffer was added, and boiled for 4 minutes in a heat block at 100°C. This process was
repeated for the HeLa cytoplasmic extract, along with the mouse brain extracts previously
prepared as mentioned above. After 2μL of protein ladder was added to the first well, 10μL of
each sample was loaded into separate wells adjacent to one another, and the power system turned
on. The gel ran at 23mA for 30 minutes, followed by 35mA for 45 minutes. After the gel
finished running, it was transferred to the western blot apparatus. A transfer sandwich was
constructed with the gel and nitrocellulose membrane oriented properly while soaking in
~600mLs of 1x transfer buffer (25mM Tris base, 192mM glycine, and 20% methanol). Once
completed, the transfer sandwich was placed in the western blot transfer apparatus and ran for 1
hour at 400mA. After the transfer was completed, the membrane was incubated in 3% dry milk
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blocking solution (3g non-fat dry milk in 100mLs of Tris-buffered saline with Tween 20[TBST]) overnight while rocking at room temperature. After pouring out the blocking solution, the
membrane was rinsed with ~50mLs of TBS-T (20mM Tris, 150mM NaCl, 0.05% Tween 20) for
3 minutes and a total of 3 washes. The membrane was incubated with the primary antibody
(1:2,000 dilution in a 1% blocking solution) for 2 hours at 4°C while rocking. After 3 washes
with TBS-T for 3 minutes, the membrane was incubated with the secondary antibody (1:20,000
dilution in a 1% blocking solution) for 1 hour at room temperature. After 3 more subsequent
washes with TBS-T for 3 minutes, the membrane was visualized at 700 nm using the Li-COR
UV spectrometer.
Results
The resulting image from the western blot demonstrated Zfp410 was detected by the
custom antibody in several extracts previously prepared from cancer cells (HeLa cytoplasmic
extract), mouse cerebellum, prefrontal cortex, hippocampus, and rat brain (Figure 2). This also
demonstrates our polyclonal antibody can be used to identify Zfp410 in multiple species, even
though the antibody was generated against a purified mouse isoform of Zfp410. Several extracts
were tested to observe which tissues Zfp410 was in, notably the whole rat brain which was used
in future experimentation. Bands above 37 kDa suggested the antibody detected other isoforms
of Zfp410 or Zfp410-like proteins (52 and 100 kDa respectively). The 52 kDa isoform of Zfp410
has been reported to be found in both human and rats, but not previously reported in mice. While
the protein ladder shows an approximate molecular weight, mass spectrometry may be necessary
to determine if the band a little higher than 50 kDa is truly the 52 kDa isoform of Zfp410.
Throughout all extracts, a band can be seen at ~75 kDa though no isoform of Zfp410 has
been identified at this molecular weight. A study reported that Zfp410 may be able to be
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sumyolated, which is a chemical modification that has been identified to increase the half-life of
proteins or may aid in the repair of damaged DNA (Benanti et al., 2002). Proteins that have been
sumoylated have been reported to run about 20-25 kDa higher, adding to their molecular weight.
If the 52 kDa isoform of Zfp410 is sumoylated, it would be reasonable to suggest that the 75 kDa
band could be a sumoylated version of Zfp410. While this was not part of the aims of the study,
if Zfp410 can be modified in such a way this may further elucidate the role it plays in cognitive
and molecular pathways.
Figure 2
Western blot showing Zfp410 in various extracts

Note. A western blot was performed using extracts from a human cancer cell line, brain tissue
obtained from mice and rats. Figure by Mariko Locke.
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Aim 2: Identification of Potential Zfp410 Binding Partners
Overview
After the polyclonal antibody had been characterized, it was ready to be used in
identifying Zfp410 interacting proteins from rat brain extracts. The co-immunoprecipitation (CoIP) assay utilizes an agarose resin that is specific to the antibody species, in this case Protein A
agarose beads were used to bind antibodies generated from a rabbit (Bergmann-Leitner et al.,
2008). Using our antibody, we formed a protein complex that binds to Zfp410 and pulls any
interacting proteins attached to it out of solution. After a series of washes to remove non-specific
proteins bound to the resin, the protein complex containing Zfp410 and its binding partners were
separated from the beads using a high salt buffer containing dithiothreitol (DTT), a reducing
agent to sever the linkage to the resin (Sousa et al., 2011). Once the protein complex was
isolated, SDS-PAGE was used in tandem with the western blot assay and silver stain analysis to
visualize and identify potential binding partners of Zfp410. Western blots identify a specific
protein, in this case all isoforms of Zfp410 were observed. Conversely, silver stain analysis is a
highly sensitive technique that provides a way to visually analyze all protein bands that were
pulled out of solution (Hempelmann & Krafts, 2017). Together these techniques allowed us to
get a visual representation of the isolated Zfp410 complex and determine which proteins could
be potential Zfp410 interacting proteins. After looking over the images, we chose a band we
thought might be an interacting protein. We then utilized tandem mass spectrometry, a technique
used to determine the identity of an unknown protein using mass spectrometry, along with a
compound library that matched the fragmentation patterns to known proteins. From this data, we
were able to purchase commercially available antibodies for each respective candidate and
confirmed them via western blot.
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Methods: Co-Immunoprecipitation, Silver Stain, and Western Blot Analysis
The ethanol-preserved Protein A agarose resin was prepared by taking 100μL and
spinning at 3,000 rpm for 2 minutes. The ethanol was removed carefully by pipetting and 50μL
of Co-IP wash buffer (20mM Tris pH 7.5, 150mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 10%
glycerol, 0.2% NP-40) was added to resuspend the resin. This step was repeated twice,
centrifuging at 3,000 rpm between each addition of wash buffer to ensure ethanol was removed
from the resin. 10μL of 10mg/mL bovine serum albumin (BSA) was added to the resuspended
resin and allowed to equilibrate on a rocker for 1 hour at 4°C. After blocking, the resin was
rinsed with 1mL of wash buffer and spun at 3,000 rpm for 2 minutes. The supernatant was
discarded, and the resin was rinsed a total of 2 times before resuspending with 50μL of wash
buffer. Once a 50/50 slurry was made, 40μL of resin was transferred to each tube. 32μL of the
appropriate antibody was added to the correspondingly labeled tube. Once the antibodies were
added, the tubes were collected and incubated at 4°C for 4 hours while rocking. After incubation,
the resin was rinsed with 1mL wash buffer followed by centrifugation for 2 minutes at 3,000
rpm. A total of two washes were completed for each tube. An extract mixture was prepared by
mixing 210μL of the previously prepared rat brain extract with 420μL of wash buffer to dilute
the extract. 300μL of the extract mixture was put into each tube, and overnight incubation at 4°C
allowed sufficient time for binding interactions to occur between the antibody and Zfp410
complex. After incubation, the resin was rinsed 2 times with 1mL of wash buffer and
centrifugation at 3,000 rpm for 2 minutes between each wash. After the final wash, the
supernatant was discarded and 30μL of elution buffer (20mM Tris pH 7.5, 500mM NaCl, 1.5mM
MgCl2, 0.2mM EDTA, 20% glycerol, and 50mM DTT added at time of use) was added to each
tube. After a 5 minute incubation followed by mixing with gentle flicking, the resin was
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centrifuged at 15,000 rpm for 2 minutes. The supernatant from each tube was collected and
moved to a fresh, appropriately labeled tube and 10uL of 4x sample buffer (250mM Tris pH 7.5,
40% glycerol, 0.04% bromophenol blue, 4% SDS, and 588mM β-mercaptoethanol) was added.
After mixing, the tubes were stored at -20°C for future use.
An SDS-PAGE gel was prepared as mentioned previously, and once solidified, 2μL of
protein ladder was loaded. Next to it, 15μL of each sample was loaded into separate wells of the
gel. Electrophoresis began at 23mA for 30 minutes, then increased to 35mA for 45 minutes until
the dye front reached the bottom of the gel. Prior to the electrophoresis run finishing, 100mLs of
10% SDS was added to a clean Pyrex dish and sat for 10 minutes before rinsing the container
with copious amounts of running water. After electrophoresis was finished, one gel was
transferred to the clean glass container and 300mLs of 50% methanol was added. The other gel
was used for western blot and the western blot protocol was followed as listed previously. The
glass container was placed on a rocker for 30 minutes at room temperature. After rocking, the
solution was discarded and 300mLs of 5% methanol was added to the container and placed on
the rocker. After 10 minutes, the solution was discarded, and the gel was rinsed with 50mLs of
RO water 3 times. A solution containing 5μM DTT in 100mLs RO water was added to the
container and placed on a rocker for 20 minutes. After the solution was discarded, 100mLs of
0.1% AgNO3 was added to the container and placed on the rocker for 20 minutes. A developing
solution was prepared by mixing 200mLs of sodium carbonate and 89μL of 37% formalin. After
the solution in the container was discarded, the gel was rinsed with 100mLs of RO water and
discarded. This was followed by two washes (50mLs each) with the developing solution. The
solution from the container was discarded in an appropriately labeled container for safe disposal
at a later time. The remaining 100mLs of developing solution was transferred to the container
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and placed on the rocker. After ~15 minutes, dark bands appeared on the gel and 5g of citric acid
was added to the container to stop the reaction. Aluminum foil was used to cover the container
for 10 minutes, before discarding the solution into an appropriate container. De-ionized (DI)
water was added to the container until imaging by a Chemi-Doc imager.
After a band was selected for tandem mass spectrometry analysis, the gel was cut using a
sterile razor blade and the gel slice placed in a clean 1.5 mL tube. The sample was sent to Duke
Proteomics for tandem mass spectrometry analysis. Confirmation assays were completed using
the methodology above using commercial antibodies at a 1:1,000 dilution and purchased from
ThermoFisher.
Results
The silver stain analysis method took several weeks to adjust the protocol, with many
long nights spent looking at various silver stain protocols and switching every reagent that was
used. After 2 months, a working silver stain protocol was verified and used to complete the
analysis portion of the Co-IP assay. Once the Co-IP conditions were empirically determined,
silver stain analysis showed several bands at sizes ranging from 37-250 kDa. The western blot
showed Zfp410 as well as other isoforms (52 kDa) and a potential Zfp410-like protein (100
kDa). Using both methods of visualization, we were able to confirm Zfp410 was pulled down
and identify a possible binding partner. The pre-immune sample served as a negative control,
which contained serum from the rabbit before immunization against Zfp410. This also showed
some background proteins that may have bound non-specifically to the Protein A resin and was
useful in determining which bands were potential interacting proteins. This sample was
compared to the Zfp410 antibody sample. The criteria for selecting potential Zfp410 interacting
proteins were bands that appeared in the Zfp410 sample but absent in the pre-immune sample
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from the silver stain. The western blot was used to determine if a band was present at that
weight, suggesting a potential isoform of Zfp410 or a similar protein in structure. Using the
previously described criteria, a band at ~180 kDa was selected as a potential binding partner of
Zfp410 (Figure 3).
Once analysis was complete and data was received from Duke Proteomics, a list of the
top 5 candidates were selected by scoring of percentage sequence coverage and molecular weight
(Table 1). The top 3 proteins in Table 1 are involved in metabolic functions of the cell, while the
proteins encoded by the genes Smarca2 and Smarca4 are involved in chromatin remodeling
complexes. If Zfp410 was confirmed to be associated with chromatin remodeling factors, such as
these two proteins, more research could be done on the role Zfp410 plays in such pathways.
Commercial antibodies were ordered for all 5 proteins and the presence of Zfp410 was
confirmed by western blotting.
Figure 3
Zfp410 co-immunoprecipitation followed by silver stain and western blot

Zfp410-like protein

Potential Zfp410
interacting protein
Zfp410 isoform
Heavy chain IgG

Note. A Zfp410 co-immunoprecipitation assay was performed followed by silver stain (left) and
western blot (right) analysis. Figure by Mariko Locke.

GENOMIC LOCALIZATION OF ZFP410

17

Table 1
Mass Spectrometry Data of Potential Zfp410 Interacting Proteins

Name of identified protein

Gene
name

Molecular
weight
(kDa)

Protein
identification
probability

Percentage
sequence
coverage

Intersectin-1

Itsn1

194

100%

29.70%

Kif21a

185

100%

23.20%

Cdc42bpb

182

100%

25.00%

SWI/SNF-related, matrixassociated, actin-dependent
regulator of chromatin, subfamily
a, type 2

Smarca2

182

100%

9.14%

Transcription activator BRG1

Smarca4

181

100%

16.20%

Kinesin family member 21A
Ser/Thr-protein kinase MRCK beta

Note: Table of potential interacting proteins with Zfp410, table by Mariko Locke.
Aim 3: Determining Locations Where Zfp410 is Bound to DNA in the Brain
Overview
After completion of the Co-IP assay, our custom antibody made against Zfp410 was
further characterized and confirmed the antibody was suitable for immunoprecipitation assays.
With this information, we were able to use this antibody for our other goal: determination of
where Zfp410 binds in the brain and if methotrexate displacement of Zfp410 results in a
cognitive deficiency. Male rats were obtained and tested after methotrexate injection by the
novel object test at one and two months post-injection. After behavioral data was collected, the
hippocampus of each rat was obtained for chromatin immunoprecipitation followed by
qualitative polymerase chain reaction (qPCR) analysis. Chromatin immunoprecipitation (ChIP)
is similar to the Co-IP assay as described in previously, however instead of studying proteinprotein interactions, the ChIP assay is used to identify protein-DNA interactions. To do this,
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crosslinking the protein/DNA complex in formaldehyde is vital for ChIP to succeed. Once the
complex is formed, our Zfp410 antibody pulls the complex out of solution and the DNA can be
purified for polymerase chain reaction analysis (PCR). This technique is used for confirmation
since a small amount of DNA is required and by the end of PCR, the small amount of DNA is
amplified multiple times. For sequencing, PCR analysis allowed us to determine if DNA was
present in our sample and provided signals to adjust the protocol if needed.
Due to the lack of literature on where Zfp410 binds to DNA, we sent an initial sample
containing DNA pulled down using our Zfp410 antibody for ChIP-Seq analysis. The sequencing
results show all the regions in the genome where Zfp410 was found on DNA, and these regions
were used to find a suitable positive control for Zfp410. An input sample containing the original
genetic material was also purified and sent as a comparison, further refining our search for
Zfp410 specific regions. After reviewing the data, 4 primers were ordered at different locations
and a total of 6 ChIPs (3 methotrexate treated rats and 3 control rats) were sent off for ChIP-Seq
analysis.
Methods: ChIP and qPCR Analysis
Fresh rat hippocampus tissue was obtained and crosslinked in 1.5% formalin/phosphate
buffered saline (PBS) solution (10mM sodium phosphate pH 7.4 and 150mM NaCl) for 15
minutes at 37°C, followed by quenching the reaction with 500μL of 2.5M glycine and incubation
on ice for at least 10 minutes. The tubes were spun at 720 rpm for 5 minutes in a chilled
centrifuge. After the supernatant was discarded, the tissue was rinsed with 2mLs of cold PBS.
The tissue was spun at 720 rpm for 5 minutes and the supernatant discarded. The cross-linked
tissue was moved to fresh tubes and frozen at -80°C for later use. About 120mgs of tissue was
weighed out and kept on ice until placed in a 1.5 mL homogenizer with 500μL of cold PBS that
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contained protease inhibitors. After the tissue was dounced 15 times on ice, 26μL of 20% SDS
was added to the solution and gently mixed. The tube was left at room temperature for 30
minutes. After the incubation period, the Branson Digital Sonifier was used at 27% amplitude for
10 seconds to sonicate the homogenized material 9 times with 1 minute rests on ice between each
10 second burst. After sonication, the material was spun in a chilled centrifuge at 15,000 rpm for
10 minutes. The supernatant was removed to a fresh tube and the pellet discarded. Then, 20μL of
the supernatant was transferred to a fresh 1.5 mL tube as an input sample. Each reaction used
100μL of the supernatant with 900μL of the ChIP dilution buffer (0.5% Triton X-100, 2mM
EDTA, 20mM Tris buffer pH 8.0, 150mM NaCl, 1mM DTT, 1 protease inhibitor tablet at time
of use, and 2μg of sonicated salmon sperm DNA). After 100μL of Protein A agarose beads were
placed into a new tube and spun down at 3,000 rpm in a centrifuge for 2 minutes, the supernatant
was removed and 50μL of 10mM TE buffer (10mM Tris-HCl pH 8.0, 0.1mM EDTA) was used
to resuspend the resin, followed by an additional centrifugation. Next, 50μL of 10mM TE buffer
was added to the beads and mixed before 20μL of resin was aliquoted to each ChIP reaction. The
tubes containing the diluted ChIP material and resin were placed on a rocker for 2 hours at 4°C.
After incubation, the tubes were spun down in a chilled centrifuge at 15,000 rpm for 1 minute.
The supernatants were transferred to appropriately labeled tubes. To the tube labeled “H3”, 3μg
of purified histone H3 antibody was added. The pre-immune antibody sample had 16μL of nonimmunized rabbit serum added, while the Zfp410 tube had 16μL of Zfp410 antibody rabbit
serum added. All tubes were placed on a rocker overnight at 4°C. 200μL of Protein A agarose
resin was transferred to a 1.5 mL tube, spun down at 3,000 rpm for 2 minutes and the supernatant
discarded. 100μL of 10mM TE buffer was added to the resin, spun at 3,000 rpm for 2 minutes
and the supernatant discarded. 100μL of 10mM TE buffer was added to the resin to prepare a
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50/50 slurry before 20μL of 10mg/mL BSA was added to the tube. 20μL of 10mg/mL sonicated
salmon sperm DNA was added to the tube, which was incubated overnight at 4°C while rocking.
The blocked resin was spun in a chilled centrifuge at 3,000 rpm for 2 minutes. After the
supernatant was discarded, the resin was washed twice with 1 mL of 10mM TE. After the
supernatant was discarded from the second wash, the resin was resuspended in 100μL of 10mM
TE buffer. The tubes containing the diluted ChIP material were placed on ice and 40μL of the
blocked resin was added to each tube. The tubes were then incubated for 2 hours at 4°C while
rocking. After incubation, the tubes were obtained and spun at 3,000 rpm in a chilled centrifuge
for 3 minutes. The supernatant was discarded, and the resin was rinsed 4 times with 1mL of ChIP
wash buffer (0.25% NP-40, 0.05% SDS, 2mM EDTA, 20mM Tris pH 8.0, 250mM NaCl,
0.1μL/mL Leupeptin, and 0.1μL/mL Aprotinin) with centrifugation as noted above between each
wash. After the last wash with ChIP wash buffer, 1mL of 10mM TE buffer was used to wash the
resin a final time. After centrifugation, the supernatant was discarded and 100μL of ChIP elution
buffer (100mM NaHCO3, 1% SDS) was added to the resin. 80μL of ChIP elution buffer was
added to the input sample and all tubes were incubated overnight in a 65°C water bath. After
incubation, the tubes were spun at 15,000 rpm for 2 minutes. The supernatant was collected and
moved to fresh tubes and 2.5μL of 20mg/mL proteinase K was added to all tubes which were
incubated at 65°C for 1 hour. After incubation, 97.5μL of 10mM TE buffer was added to all
tubes before adding 200μL of the bottom layer of phenol:chloroform:isoamyl alcohol (PCIAA).
Each tube was mixed by vortexing thoroughly, followed by centrifugation at 15,000 rpm for 5
minutes. The aqueous layer was moved to a fresh tube and the rest discarded. The PCIAA step
was repeated and followed by centrifugation. After the supernatant was removed to a new tube,
200μL of chloroform was added and vortexed thoroughly. The tubes were centrifuged at 15,000
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rpm for 5 minutes and the top layer was moved to a fresh tube. A solution containing 20μL of
3M NaOAc, 3 volumes of 100% ethanol, 1.5μL of 10mg/mL glycogen was added to each tube
and incubated at -80°C overnight. The tubes were spun at 15,000 rpm for 20 minutes in a chilled
centrifuge. After the supernatant was removed, 300μL of 70% ethanol was used to rinse the
pellets. The tubes were quickly vortexed, then spun at 15,000 rpm for 5 minutes. The supernatant
was removed, and the pellets were allowed to air dry before resuspending in 50μL of molecular
grade water.
After resuspending the DNA in 50μL of molecular grade water, the master mix solutions
for qPCR were prepared. The primer set designed around the gene of interest with a potential
putative binding site (Hpn) had been ordered from IDT (Table 2). Conditions taken into
consideration during primer design were: optimal Tm of 60°C, the PCR product to be between
80-140 bases, GC clamp, GC content between 40-60%, and the length of the PCR primers were
between 18-22 bases. A 100mM primer stock was prepared for each primer set. Each PCR
reaction contained 2μL of 100mM primer stock, 6μL of molecular grade water, 10μL of 2X
Sybr-Green PCR master mix, and 2μL of DNA for a final volume of 20μL. PCR ran according to
the following scheme: 98°C for 3 minutes, 98°C for 10 seconds, 55°C for 30 seconds, 65°C for 5
seconds, then 95 °C for 5 minutes. A total of 50 amplification cycles were completed.
Results
After the behavioral tests were completed and scored, the rat hippocampus tissue was
collected for ChIP. The methotrexate treated rats showed cognitive decline in comparison to the
controls, as expected. Since ChIP assays are typically done on a monolayer of cells and our
model utilizes hippocampus tissue from rats, the protocol required further development to
maximize the efficiency of the assay. One of the steps taken to refine our protocol was

GENOMIC LOCALIZATION OF ZFP410

22

determining how many sonications were necessary for our immunoprecipitation to work.
Sonication applies a high frequency that ruptures cell membranes and shears DNA into smaller
pieces. This process is vital to ensure the chromatin is an appropriate size prior to purification
and analysis by qPCR. After several weeks of experimentation, it was empirically determined
that 9 sonications were required to obtain DNA that ranges from 200-1000 bases in size. DNA
that is too large may be more difficult to replicate during PCR, and DNA extracted that is less
than 200 bases may form primer dimers.
Table 2
Primer sequences designed to identify Zfp410
Genes

Forward Sequence

Reverse Sequence

Hpn

CATAGGCAGGCACTGACAC

TGGAAGAGCAGCTAATACCC

Chr1

GCTATGCTGTGCTGTTCCAG

ACAGTGGGGTGGAGAAAGAC

Chr7

GCTCCAACTTAACGCTACGC

AGGTGGACCAACAAGAGCAC

Chr9

GAATACACGACTGGGTGCAG

CTGGGGGAGGGAATGTAAAC

Hpn

CCTTGGCTTCCCGAATG

GCAAAACCTGGGAGATGG

Chr1

AAGAGGAGCCAAGGATAGGC

CCTGTGACCAGTGTGGAATG

Positive
controls

Negative
controls

Note: Table of PCR primers designed, table by Mariko Locke.
For the initial part of this assay, a histone H3 antibody was used as a positive control due
to the abundance of histones within the genome (Duan et al., 2019). The negative control
contained no antibody, while the pre-immune serum from the rabbit showed the background
signal during qPCR. After bioinformatics analysis and searching for a homologue of the genes
affected by folate deficiency, a putative Zfp410 binding site was determined at the Hpn gene
located on chromosome 1 in rats (Lawton et al., 2020). Once the binding site was determined

GENOMIC LOCALIZATION OF ZFP410

23

using the putative motif for Zfp410, a forward and reverse primer set was designed around this
region. A negative control primer set was designed to confirm the specificity of the binding site,
and an absence of Zfp410 was predicted at this region in the genome. A series of input dilutions
were used to compare the efficiency of the immunoprecipitation to 5%, 0.5%, 0.05%, and
0.005% of the DNA in the original sample. The results included an abundant signal of the
positive control (histone H3) at the region away from the Zfp410 binding site, and low Zfp410
signal. In contrast, at the Zfp410 binding region of Hpn an abundant histone H3 signal was
observed along with a signal from the Zfp410 immunoprecipitation. In addition, the Zfp410
signal appeared to be similar to the histone H3 signal (Figure 4). This suggests that Zfp410 is
abundant at this region when compared to H3.
Figure 4
PCR analysis of H3 and Zfp410 ChIP assay

Note. PCR analysis of H3 and Zfp410 ChIP assay in chromosome 1 in rats was performed for
ChIP-Seq analysis to identify more regions where Zfp410 is found in the rat genome. Figure by
Mariko Locke.
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Since the literature lacks confirmed locations where Zfp410 binds to DNA in the brain,
the ChIP material obtained from using our Zfp410 antibody was sent off for sequencing (ChIPSeq analysis) to identify more regions in the genome that may have Zfp410 bound more
frequently than at Hpn. The initial data gave us 77,986 regions where Zfp410 was found to be
bound to DNA after sequencing and subsequent bioinformatics analysis. Of the regions that were
identified, there were 8,742 out of 77,986 that were found to be near a promoter region. This
supports the finding that Zfp410 is a transcription factor, due to its location on DNA relative to
the transcription pathway. Not all regions at a promoter will be used to confirm the location of
Zfp410 since the data needs to be reviewed for reproducibility. Shown in Figure 5, 3 of the
77,986 peaks were chosen as positive controls. These were chosen based on fold enrichment,
which compares Zfp410 to the input (background signal). In Figure 5A-C, the peaks represent
the amount of DNA bound to Zfp410 at localized regions and confirm our antibody successfully
pulled down the Zfp410-DNA complex (note the y axis in Figure 5A-C). Additionally, these
peaks show that the correct number of sonications were used to shear DNA down to the
appropriate size. We obtained good resolution, largely in part due to the appropriate rounds of
sonication done. The bar at the top of Figure 5A-C shows 1,000 bases and the peaks are well
within that range as we expected the DNA to be about 200-1,000 bases long. From a
bioinformatics standpoint, if the range of the peak is short there will be less DNA from which to
search for a binding sequence for Zfp410.
A total of 4 sets of primers were designed for these regions (3 positive controls and 1
negative control) and ordered. Figure 5D shows the percent input of the Zfp410
immunoprecipitation (IP) sample, the non-specific pre-immune IP, and the no antibody IP. This
compares the amount of DNA bound to Zfp410 to all of the DNA present in the original sample.
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Additionally, the fold enrichment between the Zfp410 IP and pre-immune IP was 7.42, showing
the signal of our Zfp410 antibody relative to a non-specific antibody.
The next step was to complete 6 ChIP assays (3 methotrexate treated rats, and 3 control
rats) and the material was sent for ChIP-Seq analysis to determine if Zfp410 was displaced by
the methotrexate injections. qPCR analysis was done to look at the efficiency of the following
ChIP assays for the 3 chosen positive control regions. The primers for chromosome 9 gave the
best qPCR data as evaluated by our qPCR criteria and is being used as the positive control to test
the reproducibility of our 6 ChIPs that were sent for sequencing (Figure 5D, note difference
between Zfp410 IP vs Pre-immune IP).
Figure 5
Initial ChIP-Seq data with PCR analysis of Chr9

Note. After the initial ChIP-Seq data was reviewed, three positive control regions were chosen
for PCR and a qualitative analysis of a MTX-treated ChIP was performed. Figure by Mariko
Locke.
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Conclusion
While transcription factors are vital in regulating cellular functions, they can also be
targeted to treat diseases. Many cancer treatments target the interactions between transcription
factor complexes to prevent oncogene expression, which prevents tumor growth (Lambert et al.,
2018). Future medical research may include targeting the interactions between Zfp410
complexes to negate the detrimental effects of methotrexate on cognition.
A paper published in 2021 demonstrated the role Zfp410 plays in repressing fetal
hemoglobin genes in mature red blood cells (Vinjamur et al., 2021). Although this study was
quite limited in the results found, it does illustrate how this transcription factor is under current
investigation by other groups and the significance it could have to further elucidating these
pathways.
A potential limit to our study was only using male rats to observe how methotrexate
influences cognition; however, female rats were also purchased. After injection and novel object
tests were completed, behavioral data demonstrated that methotrexate treated females did not
experience as much of a cognitive deficit as male rats did. This could suggest that female rats are
more resilient to combatting the effects of methotrexate and that these pathways may be
important for those studying brain fog caused by methotrexate.
The aims of the project have been completed since several potential Zfp410 interacting
proteins and regions within the rat genome where Zfp410 is bound have been identified. The
results obtained from this project sets the foundation for further investigation on Zfp410 and its
functions. Additionally, more work in the lab can be done to redo experiments to demonstrate the
data is reproducible and determine if Zfp410 is found at the same location in 3-6 different rats by
qPCR analysis. Further bioinformatics refinement can also be done to narrow the number of
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peaks chosen for confirmation assays as well as compile a gene ontology report to determine the
cellular locations, biological processes, and specifically the molecular functions that are
impacted by Zfp410.
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